Esperoct
Payments companies reported to CMS as associated with Esperoct. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Esperoct, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Esperoct
These are the largest totals companies reported as associated with Esperoct. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Shveta Gupta | Orlando, FL | Pediatric Hematology-Oncology | $41,279.13 |
| Richard Lemons | Salt Lake City, UT | Pediatric Hematology-Oncology | $30,682.62 |
| Dennis Borrero Ramos | Orlando, FL | Pediatric Hematology-Oncology | $21,176.22 |
| Doris Quon | Los Angeles, CA | Hematology (Internal Medicine) | $20,250.21 |
| Kim Schafer | Sacramento, CA | Family | $13,628.84 |
| Daisy Cortes | Las Vegas, NV | Pediatric Hematology-Oncology | $13,525.69 |
| Paulette Bryant | Charlotte, NC | Pediatric Hematology-Oncology | $8,038.76 |
| Jennifer Domm | Nashville, TN | Pediatric Hematology-Oncology | $7,306.03 |
| Akshat Jain | Redlands, CA | Pediatric Hematology-Oncology | $4,500.00 |
| Fernando Corrales-Medina | Miami, FL | Pediatric Hematology-Oncology | $4,029.00 |
Prescribed Esperoct?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.